AVEO Pharmaceuticals Inc. licensed exclusive worldwide development and commercialization rights to the company's preclinical antibodies targeting the RON (Recepteur d'Origine Nantais) receptor to Centocor Ortho Biotech Inc., of Horsham, Pa., a wholly owned subsidiary of Johnson & Johnson, for $15 million up front, as much as $540 million in milestones and double-digit royalties on worldwide net sales.